During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with ...

Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC ...

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

This week in oncology has been marked by significant strides in targeted therapies, a re-evaluation of established treatment paradigms, and compelling evidence for the impact of lifestyle ...

Living in food deserts, clinical trial deserts, and areas with high transportation vulnerability significantly lowers breast ...

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with ...

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral ...